Resumen de acción TLPP.F Telix Pharmaceuticals Limited, empresa biofarmacéutica en fase comercial, se centra en el desarrollo y la comercialización de radiofármacos terapéuticos y de diagnóstico para el cáncer y las enfermedades raras en Australia, Bélgica, Japón, Suiza y Estados Unidos. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Telix Pharmaceuticals Limited Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Telix Pharmaceuticals Precios históricos de las acciones Precio actual de la acción AU$14.28 Máximo en las últimas 52 semanas AU$16.74 Mínimo de 52 semanas AU$6.16 Beta 2.41 Cambio en 1 mes -10.44% Variación en 3 meses -1.37% Cambio de 1 año 123.07% Variación en 3 años 128.79% Variación en 5 años 1,299.66% Variación desde la OPV 1,209.77%
Noticias y actualizaciones recientes
Telix Pharmaceuticals Limited Submits its Biologics License Application to the United States Food and Drug Administration for TLX250-CDx (Zircaix, Zr- girentuximab) Kidney Cancer Imaging Jan 01
Telix Pharmaceuticals Limited Completes the Installation of Two New Cyclotron at Telix Manufacturing Solutions in Brussels South, Belgium Dec 19
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent Oct 24 Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy Oct 08 Ver más actualizaciones
Telix Pharmaceuticals Limited Submits its Biologics License Application to the United States Food and Drug Administration for TLX250-CDx (Zircaix, Zr- girentuximab) Kidney Cancer Imaging Jan 01
Telix Pharmaceuticals Limited Completes the Installation of Two New Cyclotron at Telix Manufacturing Solutions in Brussels South, Belgium Dec 19
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent Oct 24 Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy Oct 08 Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy
Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma Oct 03
Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million. Sep 23
Telix Submits NDA for TLX101-Cdx (Pixclara®) Brain Cancer Imaging Agent Aug 28
Telix Pharmaceuticals Limited Announces Expanded Access Program Opens in the U.S. for Tlx101-Cdx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent Jul 30 Telix Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024 Telix Pharmaceuticals Limited has withdrawn its Follow-on Equity Offering in the amount of $201.79 million. Jun 15
Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent May 28
Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million. May 19 Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million. May 18
Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024 Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of ARTMS, INC.
Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million. Apr 11
Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million. Apr 09
Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent Mar 26 Telix Pharmaceuticals Limited (ASX:TLX) signed an agreement to acquire ARTMS, INC. for approximately $84 million. Mar 05
Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million. Feb 27 Telix Pharmaceuticals Limited Provides Earnings Guidance for Full Year Revenue 2024
Telix Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 22, 2024 Jan 08
Telix Pharmaceuticals Limited Announces Executive Changes Dec 20
Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer Dec 19
Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent Dec 04
Telix Pharmaceuticals Limited Announces Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS Nov 30
Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million. Nov 15
Telix Pharmaceuticals Limited (ASX:TLX) acquired Lightpoint Surgical Limited from Lightpoint Medical, Ltd AUD 51 million. Nov 02 Telix Pharmaceuticals Limited Announces Positive Preliminary Results from the Phase I ProstACT SELECT Study of Its rADC Therapy Candidate TLX591 Oct 19
Telix Pharmaceuticals Limited Announces First Patients Dosed in Chinese Imaging Studies Oct 18
Telix Pharmaceuticals Limited to Report Q3, 2023 Results on Oct 18, 2023 Oct 11
Telix Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 23, 2023 Aug 15
Telix Pharmaceuticals Limited to Report Q2, 2023 Results on Jul 19, 2023 Jul 13
Telix Pharmaceuticals Limited to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI Jun 24
Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire Lightpoint Surgical Limited from Lightpoint Medical, Ltd for AUD 51 million. Jun 22
Telix Pharmaceuticals Limited Announces First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion Jun 19
Telix Pharmaceuticals Limited Announces Detailed Positive Results from its Completed Pivotal Phase III ZIRCON Trial Feb 20
Telix Pharmaceuticals Limited to Report Q4, 2022 Results on Jan 18, 2023 Jan 12
Telix Pharmaceuticals Limited Announces ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances Dec 22
Telix Pharmaceuticals Limited Announces Leadership Changes Dec 05
Telix Pharmaceuticals Limited Announces Illuccix Kit for the Preparation of Gallium Ga 68 Gozetotide Injection Nov 23
Telix Pharmaceuticals Limited Announces That First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy Nov 22
Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire Optimal Tracers from Northern California PET Imaging Center. Nov 15
Telix Pharmaceuticals Limited Announces Positive Topline Results from Overseas Phase III Clinical Trial Has Met Clinical Endpoints Nov 11
Telix Pharmaceuticals Limited Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study Nov 07
Telix Pharmaceuticals Limited Presents Preliminary Data on TLX250-CDx Indication Expansion at EANM Oct 18 Telix Pharmaceuticals Limited to Report Q3, 2022 Results on Oct 20, 2022 Telix Pharmaceuticals Limited Announces Health Canada Approves Illuccix for Prostate Cancer Imaging Oct 14
Telix Pharmaceuticals Limited Announces First Patient in New Zealand Dosed with Illuccix Sep 30 Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
Telix Pharmaceuticals Limited and GenesisCare announce First Patient Enroll in ProstACT TARGET Study Sep 27
Telix Pharmaceuticals Limited Reports the Final Results from the IPAX-1 Ph I/II Study of TLX101 Therapy Iodo-Phenylalanine Sep 21
Telix Pharmaceuticals Limited and Atonco S.A.S. Announce That the Final Patient Dosed in A Phase I Study of TLX250-CDx in Patients with Non-Muscle Invasive Bladder Cancer Aug 24
Telix Pharmaceuticals Limited to Report First Half, 2022 Results on Aug 18, 2022 Aug 05
Telix Pharmaceuticals Limited Reports on APAC Regulatory Progress Prostate and Kidney Cancer Imaging Aug 02 Telix Pharmaceuticals Limited Appoints Kevin Richardson as CEO, Telix Americas Telix Pharmaceuticals Limited Announces Management Change
Telix Pharmaceuticals Limited Provides Reimbursement and Launch Updates May 30
Telix Pharmaceuticals Limited Announces First Patient Has Been Dosed in the 'STARLITE 2' Phase II Study of the Company's Investigational Renal Cancer Therapy, TLX250 (177Lu-DOTA-girentuximab), At Memorial Sloan Kettering Cancer Center (MSK) in New York May 05
Telix Pharmaceuticals Limited Announces First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent Apr 16
Telix Pharmaceuticals Limited Announces ProstACT TARGET Phase II Clinical Trial Update Apr 12
Telix Pharmaceuticals Limited Announces Commercial Launch of Illuccix in the United States Apr 04
Telix Pharmaceuticals Limited Announces Board Changes Mar 31 Telix Pharmaceuticals Limited Completes ZIRCON Phase 3 Imaging Study Targets Enrolment Mar 10
Telix Pharmaceuticals Limited, Annual General Meeting, May 18, 2022 Feb 25
Telix Pharmaceuticals Limited Appoints Darren Smith as Deputy Group Chief Financial Officer Feb 04
Telix Pharmaceuticals Limited to Report Fiscal Year 2021 Results on Feb 24, 2022 Feb 03
Telix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 175.000002 million. Jan 28
Telix Pharmaceuticals Limited Doses 1St Patient in Prostact Prostate Cancer Therapy Program Jan 27
Telix Pharmaceuticals Limited and Atonco S.A.S. Announces That First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer Dec 21
Telix Pharmaceuticals Limited announces FDA Approves Prostate Cancer Imaging Product, Illuccix® Dec 20
Telix Pharmaceuticals Limited Announces Illuccix EU Regulatory Submission Progress Update Dec 11
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil Dec 02
Telix Pharmaceuticals Limited Announces FDA Extends New Drug Application Review Period for Illuccix Sep 24
Telix Pharmaceuticals Limited Announces That the United States Food and Drug Administration (Fda) Has Accepted the Investigational New Drug Application Sep 15
Telix Pharmaceuticals Limited Announces That the Last Patient Has Been Imaged in Phase I Clinical Study of Telix's Investigational Prostate Cancer Imaging Product Tlx591-CDx in Collaboration with Kanazawa University Sep 09 Great Ormond Street Hospital Receives UK Research Ethics Approval to Commence A Phase II Academic Study of Telix’s Investigational Product, TLX66 (90Y-DTPA-Besilesomab) Rentabilidad de los accionistas TLPP.F US Biotechs Mercado US 7D -7.9% -1.9% -2.8% 1Y 123.1% -5.7% 24.1%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: TLPP.F superó a la industria US Biotechs, que obtuvo un rendimiento del -5.7% el año pasado.
Rentabilidad vs. Mercado: TLPP.F superó al mercado US, que obtuvo un rendimiento del 24.1% el año pasado.
Volatilidad de los precios Is TLPP.F's price volatile compared to industry and market? TLPP.F volatility TLPP.F Average Weekly Movement 6.6% Biotechs Industry Average Movement 10.9% Market Average Movement 6.3% 10% most volatile stocks in US Market 18.0% 10% least volatile stocks in US Market 3.1%
Precio estable de las acciones: TLPP.F no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de TLPP.F (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Telix Pharmaceuticals Limited, una empresa biofarmacéutica en fase comercial, se centra en el desarrollo y la comercialización de radiofármacos terapéuticos y de diagnóstico para el cáncer y las enfermedades raras en Australia, Bélgica, Japón, Suiza y Estados Unidos. La empresa ofrece Illuccix para el tratamiento del cáncer de próstata y TLX66-CDx para el tratamiento de la osteomielitis por imágenes. Entre sus productos candidatos figuran TLX591, un conjugado radioanticuerpo-fármaco para el tratamiento del cáncer de próstata; TLX250-CDx para el tratamiento y diagnóstico del cáncer renal (riñón); TLX101-CDx para el cáncer cerebral (glioma); TLX66-CDx para tratar el acondicionamiento de la médula ósea; TLX300-CDx para el tratamiento y diagnóstico del sarcoma de tejidos blandos; y TLX250 para el tratamiento del carcinoma de células renales claras.
Mostrar más Resumen de fundamentos de Telix Pharmaceuticals Limited ¿Cómo se comparan los beneficios e ingresos de Telix Pharmaceuticals con su capitalización de mercado? Estadísticas fundamentales de TLPP.F Capitalización bursátil US$4.95b Beneficios(TTM ) US$30.51m Ingresos (TTM ) US$400.49m
162.2x Ratio precio-beneficio (PE)
12.4x Ratio precio-ventas (PS) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de TLPP.F Ingresos AU$645.68m Coste de los ingresos AU$240.33m Beneficio bruto AU$405.35m Otros gastos AU$356.16m Beneficios AU$49.19m
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) 0.15 Margen bruto 62.78% Margen de beneficio neto 7.62% Ratio deuda/patrimonio 2.9%
¿Cómo se ha desempeñado TLPP.F a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/01/02 06:24 Precio de las acciones al final del día 2025/01/02 00:00 Beneficios 2024/06/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Telix Pharmaceuticals Limited está cubierta por 14 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Russell Wright Barclay Pearce Capital Pty Limited John Hester Bell Potter Andrew Paine CLSA
Mostrar 11 más analistas 
